Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

This trial is testing a treatment called temsirolimus — a drug that blocks a cell growth pathway called mTOR — delivered directly into the brain's blood supply (via a specialized infusion technique) for people with high-grade glioma (aggressive brain tumors, grade 3 or 4) in the frontal lobe. The drug is given this way to get higher concentrations to the tumor while reducing body-wide side effects. **You may be eligible if...** - You have a confirmed high-grade glioma (grade 3 or 4) in the frontal lobe - Your tumor has been tested and shows signs of mTOR pathway activation (through specific genetic changes or protein markers) - You have completed standard treatment (the Stupp protocol: radiation + temozolomide) - You have measurable tumor remaining **You may NOT be eligible if...** - Your tumor is in a location other than the frontal lobe - Your tumor does not show mTOR pathway activity - You have not completed the standard Stupp treatment - You have certain vascular or blood clotting problems Talk to your doctor to see if this trial is right for you.